Literature DB >> 26379884

Celecoxib can suppress expression of genes associated with PGE2 pathway in chondrocytes under inflammatory conditions.

Tian-Wen Sun1, Zhi-Hong Wu2, Xi-Sheng Weng2.   

Abstract

This study aimed to investigate the effect of a selective cyclooxygenase-2 (COX-2) inhibitor (celecoxib) on the expression of arachidonate-associated inflammatory genes in cultured human normal chondrocytes. Normal chondrocytes were obtained from the cartilage of three different amputated patients without osteoarthritis (OA). Affymetrix Human microarray was used to assess the alterations in gene expression in three groups of cells: untreated cells (negative control group), cells treated with interleukin-1β (IL-1β) (positive control group), and cells treated with IL-1β and celecoxib. The patterns of up-regulation and down-regulation of gene expression were further validated by real-time PCR. A total of 1091 up-regulated genes and 1252 down-regulated genes were identified in the positive control group compared with the negative control group. Among them, PTGS2, ADAMTS5, PTGER2, mPTGES and PTGER4 are known to be involved in chondrocyte inflammation, while VEGFA, BCL2, TRAF1, CYR61, BMP6, DAPK1, DUSP7, IL1RN, MMP13 and TNFSF10 were reported being associated with cytokine and chemokine signaling. 189 up-regulated genes and 177 down-regulated genes were identified in the positive control group compared with intervention group. PTGS1, PTGS2, ADAMTS5, PTGER2, mPTGES and PTGER4 were among the genes down-regulated upon the treatment with celecoxib. Our results demonstrated that the OA chondrocytes are the site of active eicosanoid production. IL-1β can activate inflammation in chondrocytes and trigger the production of various proteins involved in cyclooxygenase pathway. The expression of genes corresponding to these proteins can be down-regulated by celecoxib. The findings indicate that the therapy with prostaglandin E2 (PGE2)-blocking agents may decrease the PGE2 production not only by direct inhibition of COX-2 activity, but also by down-regulating the expression of genes encoding for COX-2, microsomal prostaglandin-endoperoxide synthase 1 (mPGES-1) and prostaglandin E receptors 4 (EP4) in the articular chondrocytes.

Entities:  

Keywords:  COX-2; Celecoxib; PGE2; articular chondrocytes; osteoarthritis

Year:  2015        PMID: 26379884      PMCID: PMC4565267     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Global analyses of gene expression in early experimental osteoarthritis.

Authors:  C T G Appleton; V Pitelka; J Henry; F Beier
Journal:  Arthritis Rheum       Date:  2007-06

3.  Modern molecular analysis of a traditional disease: progression in osteoarthritis.

Authors:  Linda J Sandell
Journal:  Arthritis Rheum       Date:  2007-08

Review 4.  Prostaglandin E receptors.

Authors:  Yukihiko Sugimoto; Shuh Narumiya
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

5.  Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.

Authors:  Yasunari Takada; Anjana Bhardwaj; Pravin Potdar; Bharat B Aggarwal
Journal:  Oncogene       Date:  2004-12-09       Impact factor: 9.867

Review 6.  Cyclooxygenase-2 and prostaglandins in articular tissues.

Authors:  Johanne Martel-Pelletier; Jean-Pierre Pelletier; Hassan Fahmi
Journal:  Semin Arthritis Rheum       Date:  2003-12       Impact factor: 5.532

7.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.

Authors:  Shishir Shishodia; Dimpy Koul; Bharat B Aggarwal
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis.

Authors:  Ana M Valdes; John Loughlin; Kirsten M Timms; Joyce J B van Meurs; Lorraine Southam; Scott G Wilson; Sally Doherty; Rik J Lories; Frank P Luyten; Alexander Gutin; Victor Abkevich; Dongliang Ge; Albert Hofman; André G Uitterlinden; Deborah J Hart; Feng Zhang; Guangju Zhai; Rainer J Egli; Michael Doherty; Jerry Lanchbury; Tim D Spector
Journal:  Am J Hum Genet       Date:  2008-05-08       Impact factor: 11.025

9.  Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.

Authors:  M A Alvarez-Soria; G Herrero-Beaumont; J Moreno-Rubio; E Calvo; J Santillana; J Egido; R Largo
Journal:  Osteoarthritis Cartilage       Date:  2008-06-10       Impact factor: 6.576

10.  Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis.

Authors:  Tetsuya Honda; Eri Segi-Nishida; Yoshiki Miyachi; Shuh Narumiya
Journal:  J Exp Med       Date:  2006-01-30       Impact factor: 14.307

View more
  3 in total

1.  Chondroprotective Effects of Ginsenoside Rg1 in  Human Osteoarthritis Chondrocytes and a Rat Model  of Anterior Cruciate Ligament Transection.

Authors:  Wendan Cheng; Juehua Jing; Zhen Wang; Dongying Wu; Yumin Huang
Journal:  Nutrients       Date:  2017-03-10       Impact factor: 5.717

Review 2.  Celecoxib in breast cancer prevention and therapy.

Authors:  Jieqing Li; Qiongyu Hao; Wei Cao; Jaydutt V Vadgama; Yong Wu
Journal:  Cancer Manag Res       Date:  2018-10-26       Impact factor: 3.989

3.  Determination of two fluoroquinolones and their combinations with hyaluronan effect in in vitro canine cartilage explants.

Authors:  Puntita Siengdee; Waranee Pradit; Siriwadee Chomdej; Korakot Nganvongpanit
Journal:  PeerJ       Date:  2019-03-12       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.